Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Clinical Outcomes of Small Bowel Adenocarcinoma.

Akce M, Jiang R, Zakka K, Wu C, Alese OB, Shaib WL, Behera M, El-Rayes BF.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30286-5. doi: 10.1016/j.clcc.2019.08.002. [Epub ahead of print]

PMID:
31606297
2.

Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin.

Nezami N, Camacho JC, Kokabi N, El-Rayes BF, Kim HS.

J Gastrointest Oncol. 2019 Oct;10(5):944-956. doi: 10.21037/jgo.2019.05.10.

3.

Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults.

Alese OB, Jiang R, Zakka KM, Wu C, Shaib W, Akce M, Behera M, El-Rayes BF.

Cancer Epidemiol. 2019 Oct 7;63:101618. doi: 10.1016/j.canep.2019.101618. [Epub ahead of print]

PMID:
31600666
4.

Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.

Tian S, Jiang R, Madden NA, Ferris MJ, Buchwald ZS, Xu KM, Cardona K, Maithel SK, McDonald MW, Lin JY, Curran WJ, El-Rayes BF, Behera M, Patel PR.

Cancer. 2019 Sep 18. doi: 10.1002/cncr.32516. [Epub ahead of print]

PMID:
31532544
5.

Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.

Zakka K, Jiang R, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Behera M, El-Rayes BF, Akce M.

J Hepatocell Carcinoma. 2019 Jul 22;6:119-129. doi: 10.2147/JHC.S215235. eCollection 2019.

6.

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Jul 4. doi: 10.1111/bcp.14054. [Epub ahead of print]

PMID:
31271459
7.

Induction Therapy in Localized Pancreatic Cancer.

Shaib WL, Sayegh L, Zhang C, Belalcazar A, Ip A, Alese OB, Akce M, Wu C, Qu Y, Maithel SK, Kooby D, Cardona K, Sarmeinto JM, El-Rayes BF.

Pancreas. 2019 Aug;48(7):913-919. doi: 10.1097/MPA.0000000000001353.

PMID:
31268982
8.

STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?

Lopez-Aguiar AG, Postlewait LM, Ethun CG, Zaidi MY, Zhelnin K, Krasinskas A, Russell MC, Kooby DA, Cardona K, El-Rayes BF, Maithel SK.

J Gastrointest Surg. 2019 May 29. doi: 10.1007/s11605-019-04261-6. [Epub ahead of print]

PMID:
31144189
9.

Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.

Gupta DR, Liu Y, Jiang R, Walid S, Higgins K, Landry J, McDonald M, Willingham FF, El-Rayes BF, Saba NF.

Oncology. 2019;97(1):49-58. doi: 10.1159/000499716. Epub 2019 May 20.

PMID:
31108497
10.

Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis.

Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG.

J Natl Cancer Inst. 2019 May 14. pii: djz073. doi: 10.1093/jnci/djz073. [Epub ahead of print]

PMID:
31086963
11.

National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.

George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM.

Cancer. 2019 Aug 15;125(16):2732-2746. doi: 10.1002/cncr.32150. Epub 2019 Apr 24. Review.

PMID:
31017664
12.

Nonsurgical Management of Rectal Cancer.

Akce M, El-Rayes BF.

J Oncol Pract. 2019 Mar;15(3):123-131. doi: 10.1200/JOP.18.00769.

PMID:
30861368
13.

Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.

Nagaraju GP, Zakka KM, Landry JC, Shaib WL, Lesinski GB, El-Rayes BF.

Int J Cancer. 2019 Sep 15;145(6):1529-1537. doi: 10.1002/ijc.32227. Epub 2019 Mar 19.

PMID:
30801702
14.

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, Goff L, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB.

Am J Clin Oncol. 2019 Apr;42(4):331-336. doi: 10.1097/COC.0000000000000524.

PMID:
30789414
15.

Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis.

Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF.

J Gastrointest Oncol. 2019 Feb;10(1):85-94. doi: 10.21037/jgo.2018.10.06.

16.

Cyclooxygenase-2 in gastrointestinal malignancies.

Nagaraju GP, El-Rayes BF.

Cancer. 2019 Apr 15;125(8):1221-1227. doi: 10.1002/cncr.32010. Epub 2019 Feb 12. Review.

PMID:
30747998
17.

Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.

Martini DJ, Liu Y, Shabto JM, Lewis C, Kline MR, Collins H, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, Master VA, El-Rayes BF, Ramalingam SS, Owonikoko TK, Harvey RD, Bilen MA.

Invest New Drugs. 2019 Feb 6. doi: 10.1007/s10637-019-00736-0. [Epub ahead of print]

PMID:
30725388
18.

High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study.

Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF.

Oncologist. 2019 Jul;24(7):911-920. doi: 10.1634/theoncologist.2018-0382. Epub 2018 Nov 27.

PMID:
30482824
19.

Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.

Shaib WL, Narayan AS, Switchenko JM, Kane SR, Wu C, Akce M, Alese OB, Patel PR, Maithel SK, Sarmiento JM, Kooby DA, El-Rayes BF.

Cancer. 2019 Jan 1;125(1):57-67. doi: 10.1002/cncr.31787. Epub 2018 Nov 20.

PMID:
30457666
20.

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.

Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.

PMID:
30420614
21.

The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.

Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD.

Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17.

PMID:
30329148
22.

The Potential of CAR T Cell Therapy in Pancreatic Cancer.

Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB.

Front Immunol. 2018 Sep 25;9:2166. doi: 10.3389/fimmu.2018.02166. eCollection 2018. Review.

23.

Curcumin analogs: Their roles in pancreatic cancer growth and metastasis.

Nagaraju GP, Benton L, Bethi SR, Shoji M, El-Rayes BF.

Int J Cancer. 2019 Jul 1;145(1):10-19. doi: 10.1002/ijc.31867. Epub 2018 Dec 11. Review.

PMID:
30226272
24.

Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials.

Owonikoko TK, Busari AK, Kim S, Chen Z, Akintayo A, Lewis C, Carthon BC, Alese OB, El-Rayes BF, Ramalingam SS, Harvey RD.

Oncology. 2018;95(3):138-146. doi: 10.1159/000488763. Epub 2018 Jun 18.

25.

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.

Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH.

Cancer. 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15.

26.

Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer.

Hurtado M, Sankpal UT, Ranjan A, Maram R, Vishwanatha JK, Nagaraju GP, El-Rayes BF, Basha R.

Crit Rev Oncol Hematol. 2018 Jun;126:201-207. doi: 10.1016/j.critrevonc.2018.03.016. Epub 2018 Apr 7. Review.

PMID:
29759562
27.

A patient-centered team approach in oncology.

Wu CS, El-Rayes BF.

Cancer. 2018 May 1;124(9):1856-1858. doi: 10.1002/cncr.31321. Epub 2018 Apr 6. No abstract available.

28.

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.

El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF.

Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21.

PMID:
29468455
29.

Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.

Kim HS, Shaib WL, Zhang C, Nagaraju GP, Wu C, Alese OB, Chen Z, Brutcher E, Renfroe M, El-Rayes BF.

Cancer. 2018 May 1;124(9):1992-2000. doi: 10.1002/cncr.31192. Epub 2018 Feb 16.

30.

Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis.

Shaib WL, Jones JS, Goodman M, Sarmiento JM, Maithel SK, Cardona K, Kane S, Wu C, Alese OB, El-Rayes BF.

Oncologist. 2018 Jun;23(6):704-711. doi: 10.1634/theoncologist.2017-0487. Epub 2018 Feb 14.

31.

Appendiceal Mucinous Neoplasms: Diagnosis and Management.

Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF.

Oncologist. 2018 Jan;23(1):137. doi: 10.1634/theoncologist.2017-0081erratum. No abstract available.

32.

Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.

Lopez-Aguiar AG, Ethun CG, Postlewait LM, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Sarmiento JM, Kooby DA, Staley CA, Maithel SK, Cardona K.

Ann Surg Oncol. 2018 Jan;25(1):290-298. doi: 10.1245/s10434-017-6140-8. Epub 2017 Oct 27.

PMID:
29079920
33.

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

Papadopoulos KP, El-Rayes BF, Tolcher AW, Patnaik A, Rasco DW, Harvey RD, LoRusso PM, Sachdev JC, Abbadessa G, Savage RE, Hall T, Schwartz B, Wang Y, Kazakin J, Shaib WL.

Br J Cancer. 2017 Nov 21;117(11):1592-1599. doi: 10.1038/bjc.2017.330. Epub 2017 Oct 3.

34.

Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.

Belalcazar A, Shaib WL, Farren MR, Zhang C, Chen Z, Yang L, Lesinski GB, El-Rayes BF, Nagaraju GP.

Cancer. 2017 Dec 15;123(24):4924-4933. doi: 10.1002/cncr.30944. Epub 2017 Aug 25.

35.

Appendiceal Mucinous Neoplasms: Diagnosis and Management.

Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C 3rd, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF.

Oncologist. 2017 Sep;22(9):1107-1116. doi: 10.1634/theoncologist.2017-0081. Epub 2017 Jun 29. Review. Erratum in: Oncologist. 2018 Jan;23 (1):137.

36.

Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.

Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF.

Cancer Lett. 2017 Aug 28;402:110-116. doi: 10.1016/j.canlet.2017.05.021. Epub 2017 Jun 3.

PMID:
28583846
37.

Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation.

Spiritos Z, Mekaroonkamol P, El-Rayes BF, Force SD, Keilin SA, Cai Q, Willingham FF.

Clin Endosc. 2017 Sep;50(5):491-494. doi: 10.5946/ce.2017.006. Epub 2017 Apr 24.

38.

Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, Mulcahy MF, Armstrong KI, Nabbout NH, Kalnicki S, El-Rayes BF, Onitilo AA, Moriarty DJ, Fitzgerald TJ, Benson AB 3rd.

J Clin Oncol. 2017 Mar;35(7):718-726. doi: 10.1200/JCO.2016.69.1667. Epub 2017 Jan 9.

39.

Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.

Xue Y, Vanoli A, Balci S, Reid MM, Saka B, Bagci P, Memis B, Choi H, Ohike N, Tajiri T, Muraki T, Quigley B, El-Rayes BF, Shaib W, Kooby D, Sarmiento J, Maithel SK, Knight JH, Goodman M, Krasinskas AM, Adsay V.

Mod Pathol. 2017 Feb;30(2):255-266. doi: 10.1038/modpathol.2016.174. Epub 2016 Oct 14.

40.

Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro.

Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M, Murata T.

Int J Oncol. 2016 Oct;49(4):1686-94. doi: 10.3892/ijo.2016.3669. Epub 2016 Aug 23.

PMID:
27633001
41.

Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.

Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK.

Cancer. 2017 Jan 1;123(2):345-356. doi: 10.1002/cncr.30321. Epub 2016 Sep 13.

42.

Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases.

Reid MD, Balci S, Ohike N, Xue Y, Kim GE, Tajiri T, Memis B, Coban I, Dolgun A, Krasinskas AM, Basturk O, Kooby DA, Sarmiento JM, Maithel SK, El-Rayes BF, Adsay V.

Mod Pathol. 2016 Dec;29(12):1575-1585. doi: 10.1038/modpathol.2016.124. Epub 2016 Sep 2.

43.

A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).

Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, El-Rayes BF.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):296-303. doi: 10.1016/j.ijrobp.2016.05.010. Epub 2016 May 24.

PMID:
27475674
44.

Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi HJ, Akkas G, Memis B, Robinson BS, El-Rayes BF, Staley CA, Staley CA, Winer JH, Russell MC, Knight JH, Goodman M, Krasinskas AM, Adsay V.

Mod Pathol. 2016 Oct;29(10):1243-53. doi: 10.1038/modpathol.2016.105. Epub 2016 Jun 24.

45.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG.

Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Review.

46.

Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement.

Gamboa AM, Kim S, Force SD, Staley CA, Woods KE, Kooby DA, Maithel SK, Luke JA, Shaffer KM, Dacha S, Saba NF, Keilin SA, Cai Q, El-Rayes BF, Chen Z, Willingham FF.

Cancer. 2016 Jul 15;122(14):2150-7. doi: 10.1002/cncr.30040. Epub 2016 May 3.

47.

Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.

Rajitha B, Nagaraju GP, Shaib WL, Alese OB, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF.

Mol Carcinog. 2017 Jan;56(1):288-299. doi: 10.1002/mc.22492. Epub 2016 Apr 29.

PMID:
27128654
48.

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.

Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM.

Med Oncol. 2016 May;33(5):48. doi: 10.1007/s12032-016-0762-8. Epub 2016 Apr 11.

PMID:
27067436
49.

Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro.

Yamaguchi M, Osuka S, Weitzmann MN, El-Rayes BF, Shoji M, Murata T.

Int J Oncol. 2016 May;48(5):1955-64. doi: 10.3892/ijo.2016.3409. Epub 2016 Feb 25.

PMID:
26935290
50.

Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.

Rajitha B, Belalcazar A, Nagaraju GP, Shaib WL, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF.

Cancer Lett. 2016 Apr 10;373(2):227-33. doi: 10.1016/j.canlet.2016.01.052. Epub 2016 Feb 2.

PMID:
26850372

Supplemental Content

Loading ...
Support Center